Opdivo shows promise as skin cancer treatment option
Once skin cancer in advanced stages has been surgically removed, Opdivo may be the best option to keep the malignancy at bay, according to a Phase 3 clinical trial sponsored by manufacturer Bristol-Myers-Squibb.
In a July 5 press release, the company confirmed the findings from the still-underway trial showing Opdivo bested rival Yervoy (also made by Bristol-Myers-Squibb) in helping patients live longer before the cancer returned.
Dr. Vicki Goodman, developmental lead of melanoma and genitourinary cancers for Bristol-Myers-Squibb, said late-stage skin cancer presents an obstacle for most patients.
“These topline results support the potential promise of Opdivo as a treatment option for patients with high-risk surgically resected melanoma,” Goodman said in the release. “There remains an unmet need for additional options as the majority of Stage III and resected Stage IV high-risk melanoma patients experience disease recurrence after surgery.”
Goodman said that next steps include petitioning regulators to authorize Opdivo for prescriptions to Stage III and IV melanoma patients.
Organizations in this story
Bristol-Myers Squibb 345 Park Ave NY, NY 10154